Excipient Microbial Limits

Pharmaceutical Excipient Microbial Limits & Objectionable Pathogens Control

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Analyzing microbial limits (TAMC/TYMC) for excipients used in sterile and non-sterile drug formulations, pathogen screens, and mycotoxin reviews.

Key answer

Microbial limits of excipients directly dictate finished product shelf life and safety. Standards follow pharmacopeias (USP <61>/<62>). Inhalation, ophthalmic, and injectable excipients require extremely low bioburden and bacterial endotoxin certification (USP <85>). Natural botanical or mineral excipients require screenings for mycotoxins and Salmonella.

Microbial Risk Profiles by Excipient Source

Synthetic chemicals have low microbial risks, whereas natural or semi-synthetic excipients represent rich organic substrates vulnerable to mold and bioburden.

  • Natural minerals (talc, bentonite): vulnerable to thermophilic spores, requiring sterilization (gamma radiation) validations
  • Botanical sources (cellulose, starch): focus on mold/yeast counts (TYMC) and moisture controls during storage
  • Parenteral excipients (dextran, polysorbate): mandatory bacterial endotoxin testing (LAL assay) to prevent pyrogenic reactions

FAQ

Can ethylene oxide (ETO) be used for excipient sterilization?+

It is highly discouraged. ETO residues are carcinogenic and react with excipient molecules to form toxic degradants (e.g. 2-chloroethanol). Gamma radiation is the preferred method, requiring evaluations of radiation dose effects on functionality (FRCs).

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.